Personalized Medicine in Psoriasis – A Long Road Ahead?
Psoriasis: Targets and Therapy · 2026-06 · Volume 16 · 1-3
DOI: 10.2147/ptt.s595079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psoriasis: Targets and Therapy, 2026-06. Verfasst von Tom M Hillary. Beteiligte Einrichtung: Department of Dermatology, University Hospital Leuven, Leuven, Belgium. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Background
Biologic therapies targeting IL‑17 and IL‑23 have revolutionized psoriasis management, enabling rapid and durable disease control. Yet treatment selection still follows a trial‑and‑error approach, and clinically validated biomarkers for personalization remain absent.
Objective
To outline current challenges in biomarker development for psoriasis and describe the design and aims of the PICASSO prospective cohort as a platform for future personalized medicine. Current Challenges: Despite evidence that IL‑17/IL‑23 inhibitors may induce disease modification through effects on effector, memory, and regulatory immune cells, reliable predictive or prognostic biomarkers have not emerged. Barriers include complex pathogenesis, universally high biologic efficacy reducing need for stratification, inconsistent findings from genetic or transcriptomic studies, and the multifactorial nature of comorbidities.
Methods
Picasso ProspectIve Cohort psoriASiS FOllow-Up: PICASSO is a 10‑year prospective biobank/registry enrolling patients within three years of disease onset. Biological samples are longitudinally linked to clinical and epidemiological data, with follow‑ups every 2.5 years. The ultimate aim is to identify biomarkers predicting disease trajectory.
Conclusion
Personalized psoriasis care requires biomarkers predicting progression and comorbidity risk. PICASSO represents a step toward disease‑modifying, preventive precision medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Leuven, Leuven, Belgium.
ORCID-Profile: Tom M Hillary
Zitieren
APA
Hillary, T. M. (2026). Personalized Medicine in Psoriasis – A Long Road Ahead?. Psoriasis: Targets and Therapy, Volume 16, 1-3. https://doi.org/10.2147/ptt.s595079
Vancouver
Hillary TM. Personalized Medicine in Psoriasis – A Long Road Ahead?. Psoriasis: Targets and Therapy. 2026;Volume 16:1-3. doi:10.2147/ptt.s595079
BibTeX
@article{Hillary2026,
author = {Hillary, Tom M},
title = {Personalized Medicine in Psoriasis – A Long Road Ahead?},
journal = {Psoriasis: Targets and Therapy},
year = {2026},
volume = {Volume 16},
pages = {1--3},
doi = {10.2147/ptt.s595079}
}
EUVIMED